Evidence map›Paper›PMID 42362553›Full record

ArticleNPJ Parkinson's disease2026

Smartphone-derived digital motor measures to monitor progression in idiopathic REM sleep behavior disorder.

Sarah Bouhadoun, Kirsten I Taylor, Stefan Lambrecht, Werner L Popp, Damian Kwasny, Michael Lindemann, Martin J McKeown, Antoine Duquette, Nicolas Jodoin, Valerie Soland and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sarah BouhadounDepartment of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.
Kirsten I TaylorRoche Pharma Research and Early Development (pRED) Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Stefan LambrechtRoche Pharma Research and Early Development (pRED) Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Werner L PoppRoche Pharma Research and Early Development (pRED) Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Damian KwasnyRoche Pharma Research and Early Development (pRED) Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Michael LindemannF. Hoffmann-La Roche Ltd, Roche Information Solutions (RIS), Data, Analytics & Research, Roche Diagnostics, Basel, Switzerland.
Martin J McKeownDepartment of Neurology, University of British Columbia, Vancouver, BC, Canada.
Antoine DuquetteDepartment of Neurology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
Nicolas JodoinDepartment of Neurology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
Valerie SolandDepartment of Neurology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
Nicolas DupréNeuroscience Research Program, Centre hospitalier universitaire de Québec (CHUQ), Quebec City, QC, Canada.
Julius AnangDepartment of Neurology, Saint Boniface Clinic, Winnipeg, MB, Canada.
Barbara S ConnollyDepartment of Neurology, Hamilton Health Sciences Centre, Hamilton, ON, Canada.
Kerrie SchofferDivision of Neurology, Dalhousie University, Halifax, NS, Canada.
David A GrimesHospital Research Institute (OHRI), Ottawa, ON, Canada.
Ronald B PostumaDepartment of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada. Ron.postuma@mcgill.ca.

Funding

CIHR 399711
6 · The paper itself

Abstract

Sensitive and scalable biomarkers are critical for tracking progression during the prodromal phase of Parkinson's disease, particularly in idiopathic REM sleep behavior disorder (iRBD). We evaluated the Roche PD Mobile Application version 2, a smartphone-based platform, in 51 individuals with polysomnography-confirmed iRBD, 89 patients with early Parkinson's disease, and 22 healthy controls over 12 months. Participants completed daily active tasks generating validated digital summary measures. Adherence was high (73%). Baseline digital bradykinesia scores discriminated between groups (p < 0.001) and were higher in phenoconverters versus non-converters (p = 0.003; Cohen's d = 1.10). Over 50 weeks, bradykinesia (Cohen's d = 0.50) and speech (Cohen's d = 0.79) scores worsened significantly. Sample size modeling showed that digital bradykinesia required 132 participants per arm to detect a 50% treatment effect, fewer than the best-performing clinical measure. These findings support digital bradykinesia as a sensitive endpoint for prodromal Parkinson's disease trials.

Identifiers

PMID42362553

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.